Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer. 
		 	 	 		


IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC 

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors 

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Biomarker Consortium

Subscribe

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia  

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Uproleselan plus 7+3 chemotherapy failed to improve EFS vs chemotherapy alone in older patients with newly diagnosed AML fit for intensive chemotherapy.


Uproleselan Plus Chemotherapy Fails to Improve EFS in Older Patients With AML 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Advances in the Treatment and Management of Myelodysplastic Syndrome (MDS): The Role of Oral HMAs

Treating CMML and AML with HMAs

Videos

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs).

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs). In this episode, gain insights about MDS risk stratification and prognosis, and why it is important to treat early.

Diagnosing and Managing Myelodysplastic Syndrome

The role of HMAs in the treatment of patients with intermediate- and high-risk MDS.

Treating Intermediate- and High-Risk MDS

Guillermo Garcia-Manero, MD, provides a high-level overview of the effectiveness of oral HMA agents in the treatment of intermediate- and high-risk MDS.

Available and Emerging Oral HMAs

An expert discusses the real-world impact of hypomethylating agents for the treatment of patients with MDS.

Real-World Use for Oral HMAs

A review of the benefits of oral HMA treatments in the management of MDS, and the impact on a patient's quality of life.

The Impact of Oral HMA Treatment Options on QOL

An expert discusses data supporting the use of HMAs in the treatment of lower-risk MDS.

The Role for HMAs in Lower-Risk MDS

An overview of how HMAs are being used to treat CMML and their use in combination with other therapies for patients with AML.

Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.

Managing AEs Associated with HMA Treatment

Insights Video Series

Treating CMML and AML with HMAs

EP: 1.Diagnosing and Managing Myelodysplastic Syndrome

EP: 2.Treating Intermediate- and High-Risk MDS

EP: 3.Available and Emerging Oral HMAs

EP: 4.Real-World Use for Oral HMAs

EP: 5.The Impact of Oral HMA Treatment Options on QOL

EP: 6.The Role for HMAs in Lower-Risk MDS

EP: 7.Treating CMML and AML with HMAs

EP: 8.Managing AEs Associated with HMA Treatment

Latest Conference Coverage